SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: David Winkler who wrote (513)5/4/1998 12:58:00 PM
From: Kevin Ponzo  Respond to of 2135
 
Angiogenesis Opportunity --

ENMD looks like a great play!

Another opportunity may be SUGEN. Per their 1997 annual report, SUGEN plans "to move SU5416 (angiogenesis drug) into multiple Phase II studies in different patient populations over the coming summer and fall". SUGEN "will continue striving to achieve the overriding goal of being first on the market".

More information is available at SUGEN's web site at www.sugen.com



To: David Winkler who wrote (513)5/4/1998 2:59:00 PM
From: muddphudd  Respond to of 2135
 
I heard from a rather reliable source that Upjohn has used thalidomide on a number of cancer patients. It appears to have an unfavorable cardiac side-effect. It compromised coronary blood flow. If this is true, and confirmed in a clinical trial, then thalidomide may not make it as an anti-angiogenesis drug. Time will tell.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News